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Abstract: As part of a program toward making analogues of amlexanox (1), currently under 
clinical investigation for the treatment of type 2 diabetes and obesity, we have synthesized 
derivative 5 in which deuterium has been introduced into two sites of metabolism on the C-7 
isopropyl function of amlexanox. The synthesis of 5 was completed in an efficient three-step 
process utilizing reduction of key olefin 7b to 8 by Wilkinson’s catalyst to provide specific 
incorporation of di-deuterium across the double bond. Compound 5 displayed nearly equivalent 
potency to amlexanox (IC50 1.1 µM vs 0.6 µM, respectively) against recombinant human TBK1. 
When incubated with human, rat, and mouse liver microsomes, amlexanox (1) and d2-amlexanox 
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(5) were stable (t1/2 > 60 min) with 1 showing marginally greater stability relative to 5 except for 
rat liver microsomes. These data show that incorporating deuterium into two sites of metabolism 
does not majorly suppress Cyp-mediated metabolism relative to amlexanox. 
Keywords:  obesity, amlexanox, d2-amlexanox, metabolites, microsomal stability, TBK1 kinase, 
Wilkinson’s catalyst  
 
1.  INTRODUCTION 
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There is currently a worldwide epidemic of obesity, which is manifesting itself as a leading risk 
factor in industrialized countries for the development of type 2 diabetes, dyslipidaemia, non-
alcoholic fatty liver disease, cardiovascular disease and some cancers.1  Obesity results from a 
sustained imbalance between calorie intake and energy expenditure and is characterized by 
chronic, low-grade inflammation in liver and adipose tissues, which in turn attenuates the actions 
of multiple hormones to produce a dysregulated metabolic state.2,3,4 Prior studies on the role of 
inflammation in the generation of insulin resistance and type 2 diabetes during obesity implicate  
an important role for the nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) 
pathway, revealing the role of two non-
canonical inhibitors of kappa B (IκB) 
kinases, TANK-binding kinase 1 
(TBK1) and inhibitor of nuclear factor 
kappa-B kinase subunit ε (IKKε), in 
insulin-independent pathways that 
promote energy storage and block 
adaptive energy expenditure during 
obesity.5,6 Since none of the currently 
available and widely used treatments for obesity addresses the underlying energy imbalance 
associated with inflammation pathways,7 we initiated a high throughput screen for small 
molecule inhibitors of the TBK1 and IKKε kinases. One hit from our screen was amlexanox (1; 
Figure 1), an approved drug developed by Takeda that is used for the treatment of canker sores, 
asthma, and allergic rhinitis.8,9 The compound is a modest inhibitor of TBK1 and IKKε and 
reproduced the effects of the IKKε knockout phenotype, which include weight loss in obese 
mice, improved insulin sensitivity, and reduced hepatic steatosis and inflammation. Amlexanox 
also increased the level of the second messenger molecule cAMP and triggered the release of the 
hormone interleukin-6 (IL-6) from fat cells thereby reducing the production of glucose. Two 
recent clinical trials indicated that amlexanox treatment effectively lowered glycated hemoglobin 
 
Figure 1.  Structures of amlexanox (1), metabolites (2 - 4) and 
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(HbA1c) in a subset of patients with obesity and type 2 diabetes.10  Despite these promising 
results, the future utility of amlexanox in the clinic for obesity and type 2 diabetes intervention 
may be limited by its solubility, modest potency, and/or metabolic profile. 
 
Previous studies by Takeda investigators showed that the oral administration of amlexanox (1) in 
mice, rats, guinea pigs, and dogs generated in plasma a major mono-hydroxyl metabolite (2) 
from oxidation of the C-7 isopropyl substituent, and two minor metabolites 3 and 411,12 (Figure 
1).  The glucuronide of 1 was also identified in rats.  In humans, the main metabolite was 2.  The 
structures of metabolites 2 and 3 have been confirmed by synthesis.13 
 
As part of a program toward making analogues of amlexanox,14,15 we decided to synthesize a 
derivative 5 (Figure 1) in which deuterium is introduced into two sites of metabolism on the C-7 
isopropyl function.  The deuterium kinetic isotope effect associated with placing deuterium at the 
site of metabolic derivatization slows metabolic activation and thus is expected to increase the 
lifetime of the active drug in vivo.16 Herein we provide data of the activity of 5 relative to 
amlexanox (1) in inhibiting TBK1 and its metabolic stability against mouse, rat and human 
microsomes. 
 
2. RESULTS AND 
DISCUSSION 
 
Synthetic chemistry.  Initial 
approaches toward 
generating d1-amlexanox, in 
which the benzylic C-7 
methine was exchanged for 
deuterium, centered on 
 
Scheme 1.  Synthesis of d2-amlexanox (5) 
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catalytic exchange chemistry.  Thus, reaction of amlexanox (1) under a variety of conditions 
(hydrogen gas, 10 – 30% palladium on activated carbon, methanol-d4, 25-50 °C) left starting 
material only.  We then focused on incorporation of deuterium through room temperature 
hydrogenation of the olefin in compound 7a, made by known procedures,13,17 with deuterium gas 
in the presence of 10% palladium on activated carbon in ethyl acetate. Thus, a control reduction 
of 7a with hydrogen gave cleanly the non-deuterated C-7 isopropyl product.  Substitution of 
deuterium for hydrogen gas yielded a new set of products with mass spectrum peaks associated 
with incorporation of more than two atoms of deuterium.  The 1H NMR spectrum suggested that 
the predominant N-Boc carboxylic methyl ester product had incorporated four atoms of 
deuterium and 13C NMR experiments on the next step hydrolysis product (analogous to 5) 
indicated the presence of seven uniquely substituted C-7 methine carbons. This showed that 
deuterium had been incorporated non-specifically into both C-7 methyl groups as well as the 
methine carbon. There is literature precedence for such scrambling of isotopic incorporation into 
benzylic and allylic sites.18 
 
After unsuccessfully surveying other heterogenous catalytic conditions, we then resorted to 
olefin reduction with a homogeneous catalyst (Scheme 1).  Employing our recently published 
methodology of introducing C-7 substituents via late-stage coupling chemistry to make 
amlexanox analogues15, we reacted tricyclic bromide 619 with 2-propenyl pinacol boronic ester 
under standard Suzuki coupling conditions to give 7b in 91% yield. Reaction with  
tris(triphenylphosphine)rhodium(I) chloride (Wilkinson’s 
catalyst) and deuterium gas, as previously described for similar 
reductions,20,21 proceeded in high yield to give key intermediate 8 
with specific incorporation of di-deuterium across the double 
bond.  Standard hydrolysis conditions as described before15 then 
provided d2-amlexanox (5) in 92% yield and 72% overall yield 
from starting ester 6. All compounds were rigorously purified by 
 
Figure 2.  Comparison 1H 
NMR spectra in DMSO-d6 for 
C-7 substituent of amlexanox 
(1) and d2-amlexanox (5). 
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flash chromatography or crystallization, and their structural assignments are supported by 
diagnostic peaks in the 1H and 13C NMR spectra and by high resolution mass spectrometry. 
Digital copies of NMR and mass spectra can be found in Supplementary Materials Online. 
 
The 1H NMR spectra of the upfield region (δ 1-3 ppm) for the C-7 isopropyl substituent (Figure 
2) clearly show clean, specific incorporation of di-deuterium into 5.  Complete collapse of the 
symmetrical pentet at δ 3.05 ppm occurs in 1 and the symmetrical doublet at δ 1.25 ppm, 
integrating for six protons, changes to an unsymmetrical doublet in 5 integrating for five protons.  
High resolution mass spectra for 5 and 8 (Supplementary Materials Online) also support specific 
incorporation of 
di-deuterium.  
 
Metabolic 
stability studies.  
Amlexanox (1) 
and d2-amlexanox 
(5) are 
moderately 
metabolized by 
human, rat and mice liver microsomes. The in vitro disappearance half-life (t1/2) of both 
compounds in all three microsomes is over 60 min (Figure 3).  During the incubation in human 
and mice liver microsomes, about 8% more unmetabolized amlexanox remains after 60 min 
compared to d2-amlexanox. However, d2-amlexanox (5) is more stable than amlexanox (1) in rat 
liver microsomes. Both compounds show greater stability in human liver microsomes relative to 
the other microsomes. Verapamil was employed as positive control compound in order to ensure 
that the microsomes and NADPH used in this study were active and that incubation conditions 
 
Figure 3.  Human (H), rat (R) and mouse (M) microsomal stability for amlexanox (1) 
and d2-amlexanox (5) 
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were appropriate to perform the studies. 
Based on the observed degradation 
patterns, amlexanox (1) and d2-
amlexanox (5) are considered to be 
stable against the three liver 
microsomes.   
 
Activity against TBK1 kinase.  d2-
Amlexanox (5) was investigated for 
inhibition of recombinant human TBK1 
as described previously.15 The IC50 
values shown were determined by dose-
response radiometric kinase assays with 
myelin basic protein as substrate, and are technically apparent IC50 values.  Each is an average of 
three separate determinations.  Since the isopropyl 
group on amlexanox is solvent exposed,14 incorporation of deuterium is not expected to affect 
inhibitor potency. Indeed, the in vitro potencies of amlexanox (1) and d2-amlexanox (5) against 
TBK1 are 0.6 ± 0.1 and 1.1 ± 0.3 µM, respectively (Figure 4 and Supplementary Materials 
Online). The difference is not statistically significant demonstrating that amlexanox can be 
deuterated without affecting inhibitor potency. 
 
3. CONCLUSIONS 
As part of a program toward making analogues of amlexanox (1), which is being evaluated 
clinically for the treatment of type 2 diabetes and obesity, we decided to synthesize a derivative 5 
to determine if placing deuterium at two sites of known metabolic activation of amlexanox might 
increase its half-life against three species of liver microsomes. Microsomes are rich in 
cytochrome (Cyp) P-450 enzymes, which are the major enzymes involved in drug metabolism 
 
Figure 4. In vitro potency of amlexanox (1) and d2-
amlexanox (5) against purified TBK1 as determine via 
radiometric kinase assay measuring phosphorylation of the 
substrate myelin basic protein. The goodness of fit (r2) for 1 
and 5 is 0.97 and 0.91, respectively, with no statistically 
significant difference via Student’s two-tailed T-test (n=4, 
reported as mean ± SD). 
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and account for about 75% of total metabolism.22  The most common pathway of Cyp-mediated 
metabolism is hydroxylation of aliphatic carbons.  
 
The data in Figure 3 show that amlexanox (1) and d2-amlexanox (5) are relatively stable against 
all three liver microsomes (t1/2 > 60 min) with amlexanox showing marginally greater stability 
relative to d2-amlexanox except for rat liver microsomes. Hence, blocking two sites of 
metabolism with incorporation of a single deuterium on the C-7 methine carbon and another on a 
flanking methyl group of 5 does not majorly suppress Cyp-mediated metabolism relative to 
amlexanox. Metabolite identification experiments will be required to expand upon these 
findings.  Additionally, synthetic chemistry needs to be developed that can specifically 
incorporate C-7 deuterium patterns (e.g., -CH(CH3)(CH2D) and -CD(CH3)2) aligned with known 
metabolites 2-4, and additional patterns (e.g., -CH(CD3)2, -CD(CD3)2) to more fully explore the 
deuterium isotope effect. 
 
4. EXPERIMENTAL 
 
4.1 Materials and instrumentation.  All starting monomers were obtained from commercial 
suppliers and were used without further purification. Routine 1H NMR spectra were recorded at 
400 or 500 MHz on a Varian 400 or 500 instrument, respectively, with CDCl3 or DMSO-d6 as 
solvent. Chemical shift values are recorded in δ units (ppm). High resolution mass spectrometry 
(HRMS) analysis was performed on an Agilent Q-TOF system. Analytical HPLC was performed 
on an Agilent 1100 series instrument with an Agilent Zorbax Eclipse Plus C18 (4.6 mm × 75 
mm, 3.5 μm particle size) column with the gradient 10% acetonitrile/water (1 min), 10−90% 
acetonitrile/water (6 min), and 90% acetonitrile/water (2 min) flow = 1 mL/min. Thin-layer 
chromatography (TLC) was performed on silica gel GHLF plates (250 µm) purchased from 
Analtech. Column chromatography was carried out in the flash mode utilizing silica gel 
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(220−240 mesh) purchased from Silicycle. Extraction solutions were dried over anhydrous 
sodium sulfate prior to concentration. 
 
4.2 Ethyl 2-amino-5-oxo-7-(prop-1-en-2-yl)-5H-chromeno[2,3-b]pyridine-3-carboxylate 
(7b). A solution of tripotassium phosphate (2.63 g, 12.4 mmol) in water (6 mL) was added 
to a nitrogen-degassed suspension of ethyl 2-amino-7-bromo-5-oxo-5H-chromeno[2,3-
b]pyridine-3-carboxylate19 (6; 750 mg, 2.07 mmol), 4,4,5,5-tetramethyl-2-(prop-1-en-2-yl)-
1,3,2-dioxaborolane (833 mg, 4.96 mmol), triphenylphosphine (271 mg, 1.03 mmol), 
Pd(OAc)2 (60.3 mg, 0.27 mmol) in p-dioxane (60 mL) in a 500 mL RB flask. The mixture 
was heated at 100 -105 °C under nitrogen for 2 h. After cooling, the mixture was diluted 
with water (50 mL) and extracted with dichloromethane (2 x 120 mL). The combined 
organic phases were dried (Na2SO4) and concentrated to leave an orange solid that was 
triturated sequentially with small volumes of ethanol and ethyl ether, collected, and dried to 
leave 7b (610 mg, 91%)  as a white solid: mp 245-247 ºC. 1H NMR (400 MHz, chloroform-
d): δ 9.16 (s, 1H), 8.38 (s, 1H), 8.31 (d, J = 2.3 Hz, 1H), 7.86 (dd, J = 8.8, 2.4 Hz, 1H), 7.47 
(d, J = 8.7 Hz, 1H), 5.86 (s, 1H), 5.49 (d, J = 1.3 Hz, 1H), 5.23 - 5.18 (m, 1H), 4.41 (q, J = 
7.1 Hz, 2H), 2.24 (dd, J = 1.5, 0.8 Hz, 3H), 1.45 (t, J = 7.1 Hz, 3H). HRMS: m/z (M+H)+: 
calcd. for C18H16N2O4: 325.1183; Found, 325.1188. 
 
4.3 Ethyl 2-amino-5-oxo-7-(propan-2-yl-1,2-d2)-5H-chromeno[2,3-b]pyridine-3-carboxylate 
(8).  Tris(triphenylphosphine)rhodium(I) chloride (Wilkinson's catalyst; 339 mg, 0.366 
mmol) was completely dissolved in anhydrous dichloromethane (10 mL) and ethanol-d1 (10 
mL) in a 250 mL 3-neck RB flask under nitrogen. The flask with the resulting clear red 
brown solution was evacuated by a water pump and then flushed with deuterium gas in a 
balloon. This flushing/evacuation procedure was repeated three more times, and then the 
mixture was stirred under deuterium gas (balloon pressure) for 20 min at room temperature. 
Then compound 7 (360 mg, 1.11 mmol) dissolved in a mixture of warm dichloromethane 
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(75 mL) and ethanol-d1 (75 mL) was added by syringe. The resulting solution was stirred at 
room temperature for 4.5 h and then concentrated to a solid that was triturated in a small 
volume of benzene.  The collected solids were further purified by flash silica gel column 
chromatography (elution with 0.5 - 1.0% methanol in dichloromethane).  Product fractions 
were combined and concentrated to leave 8 (315 mg, 86%) as a while solid: mp 239-241 ºC. 
1H NMR (400 MHz, chloroform-d): δ 9.16 (s, 1H), 8.34 (s, 1H), 8.11 (d, J = 2.3 Hz, 1H), 
7.59 (dd, J = 8.6, 2.3 Hz, 1H), 7.44 (d, J = 8.6 Hz, 1H), 5.84 (s, 1H), 4.41 (q, J = 7.1 Hz, 
2H), 1.44 (t, J = 7.1 Hz, 3H), 1.30 (d, J = 6.5 Hz, 5H). HRMS: m/z (M+H)+  Calcd. for 
C18H16D2N2O4: 329.1465; Found 329.1480. 
 
4.4 2-Amino-5-oxo-7-(propan-2-yl-1,2-d2)-5H-chromeno[2,3-b]pyridine-3-carboxylic acid 
(d2-amlexanox; 5).  To a suspension of 8 (460 mg, 1.4 mmol) in ethanol (80 mL) and water 
(10 mL) was added 1 N aq. NaOH (10 mL) and the mixture was stirred at 50 °C for 90 min. 
TLC (5% methanol in dichloromethane) showed consumption of starting material. The 
mixture was filtered and the filtrate concentrated to a wet solid that dissolved in water (50 
mL). The solution was acidified with 1 N aq. HCl to pH ~3 and the precipitated solids were 
stirred at room temperature for 20 h. After storage at room temperature for another 24 h, the 
solids were collected, washed with water, and dried under vacuum at 60 °C for 4 h to leave 5 
(385 mg, 92%) as an off-white solid: mp > 300 ºC (dec.). 1H NMR (500 MHz, DMSO-d6): δ 
13.45 (s, 1H), 8.80 (s, 1H), 8.25 (b, 2H), 7.92 (d, J = 2.3 Hz, 1H), 7.73 (dd, J = 8.6, 2.4 Hz, 
1H), 7.53 (d, J = 8.6 Hz, 1H), 1.24 (d, J = 8.6 Hz, 5H). 13C NMR (101 MHz, DMSO-d6): δ 
174.84, 167.35, 162.25, 161.46, 153.02, 144.93, 141.35, 133.71, 122.44, 120.91, 118.04, 
106.23, 105.94, 33.70 – 31.07 (m), 23.64, 23.58 – 23.11 (m).  HRMS: m/z (M+H)+ Calcd. 
for C16H12D2N2O4: 301.1152; Found 301.1157.  HPLC: tR, 6.42, purity 98.3% 
 
4.5 Metabolic stability studies.  The in vitro metabolism study of amlexanox and d2-
amlexanox were performed in human, rat and mice liver microsomes to evaluate the potential of 
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each compound for cytochrome P450-mediated metabolism. The metabolic stability was 
assessed as described using pooled CD-1 mouse liver microsomes, pooled SD rat liver 
microsmes and pooled human liver microsomes (purchased from Xeno Tech). 1 μM of each 
compound was incubated with 0.5 mg/mL liver microsomes and 1.7 mM cofactor β-NADPH in 
0.1 M phosphate buffer (pH = 7.4) containing 3.3 mM MgCl2 at 37 °C. The DMSO 
concentration was less than 0.1% in the final incubation mixture. At 0, 5, 10, 15, 30, 45, and 60 
min of incubation, 40 µL of reaction mixture were removed and the reaction stopped 
immediately by adding 3-fold excess of cold acetonitrile containing 100 ng/mL of internal 
standard for quantification. The incubation without the addition of NADPH was used as a 
negative control. Verapamil were incubated similarly as a positive control substrate.  The 
collected fractions were centrifuged at 15000 rpm for 10 min to collect the supernatant for 
LC−MS/MS analysis, from which the amount of remaining compound was determined. The 
natural log of the amount of compound remaining was plotted against time to determine the 
disappearance rate and the half-life of tested compounds.  The LC−MS/MS method consisted of 
a Shimadzu HPLC system and chromatographic separation of tested compound was achieved 
using a Waters XBridge-C18 column (5 cm × 4.6 mm, 3.5 μm). An AB Sciex QTrap 5500 mass 
spectrometer equipped with an electrospray ionization source (Applied Biosystems, Toronto, 
Canada) in the negative-ion multiple reaction monitoring (MRM) mode for detection. The 
mobile phases were 0.1% formic acid in purified water (A) and 0.1% formic acid in acetonitrile 
(B). The gradient (B) was held at 10% (0-0.5 min), increased to 95% at 2 min, kept at isocratic 
95% B for 1.0 min, and then immediately stepped back down to 10% for a 2 min re-
equilibration. Flow rate was set at 1.0 mL/min. Amlexanox, d2-amlexanox and internal standard 
4-ASA were detected on the mass spectrometer by using multiple reaction monitoring transitions 
297.1 → 253.2 m/z, 299.2 → 255.1 m/z and 152.0 → 108.0 m/z, respectively. Mass spectrometry 
parameter optimization was performed using an automated quantitative method provided by the 
manufacturer. 
 
This article is protected by copyright. All rights reserved.
4.6 Kinase assay.  The assay was performed as described previously.15 Briefly, 50 nM 
purified TBK1 was incubated with 5 µM myelin basic protein and varying concentrations of 
inhibitor (from 10 µM to 0 µM). Reactions were initiated by the addition of 10 µM ATP spiked 
with [γ-32P]-ATP and allowed to proceed for 30 min at room temperature. After quenching the 
reactions, radioactive phosphorylated substrate was quantified via phosphorimaging plates. 
Results were analyzed with GraphPad Prism 7 and fit to an inhibition dose-response sigmoidal 
curve with the Hill slope constrained to -1. Assays were repeated four independent times and the 
results reported as mean ± standard deviation. Statistical significance was determined via 
Student’s two-tailed T-test (p<0.05). 
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Additional Supporting Information may be found online in the supporting information tab for 
this article (1H NMR and high resolution mass spectra data for compounds 1, 5, 7a and 8, 13C 
NMR spectra for 1 and 5, HPLC for 5, and gels from radiometric kinase assays for 1 and 5).  
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 A derivative of the TBK1 inhibitor amlexanox (1) has been synthesized with deuterium introduced into two 
sites of metabolism on the C-7 isopropyl function. d2-Amlexanox (5) displayed nearly equivalent potency 
to amlexanox (IC50 1.1 µM vs 0.6 µM, respectively) against recombinant human TBK1.  When incubated 
with human, rat, and mouse liver microsomes, 1 and 5 were stable (t1/2 > 60 minutes) with 1 showing 
marginally greater stability relative to 5 except for rat liver microsomes. 
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